Levobupivacaine to the Surgical Wound Following Cesarean

Sponsor
Manuel Ángel Gómez-Ríos (Other)
Overall Status
Completed
CT.gov ID
NCT01458431
Collaborator
(none)
70
1
2
35
2

Study Details

Study Description

Brief Summary

The postoperative period following cesarean is associated with moderate to severe pain that requires a considerable amount of analgesics that carry with them side-effects such as nausea, vomiting, fatigue and immobilization. Several studies have tried, with variable results, to find a more effective analgesia alternative such as infusion of local anesthetics through a catheter in the surgical wound sinus, a practice that has currently been widely used in clinical practice. Despite existing references on its use in the postoperative period following cesareans there continues to be a lack of information on other aspects. The investigators study hypothesis is that the use of levobupivacaine in the surgical wound will reduce the surface of hyperalgesia compared to the control group.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy of Continuous Infusion of Levobupivacaine to the Surgical Wound Following Cesarean
Study Start Date :
Oct 1, 2011
Actual Primary Completion Date :
Sep 1, 2014
Actual Study Completion Date :
Sep 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Levobupivacaine

Continuous levobupivacaine subfascial infusion

Drug: Levobupivacaine
continuous levobupivacaine subfascial infusion
Other Names:
  • local anesthetic
  • Placebo Comparator: NaCl

    Continuous NaCl subfascial infusion

    Drug: NaCl
    continuous NaCl subfascial infusion
    Other Names:
  • Placebo
  • Outcome Measures

    Primary Outcome Measures

    1. Area of incisional secondary hyperalgesia [72 hours]

    Secondary Outcome Measures

    1. Pain relief [72 hours]

    2. consumption of morphine (mg) and paracetamol (gr) [48 hours]

    3. Incidence of chronic pain [6 month]

    4. Pharmacokinetic variables of levobupivacaine [72 hours]

      Cmax, Area Under Curve, Tmax

    5. Incidence of complications and/or side effects related to the technique [72 hours]

    6. Rate of satisfaction experienced by the patients through a survey [72 hours]

    7. endocrin-metabolic response [72 hours]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Full-term pregnant women who undergo scheduled cesarean surgery under intradural anesthesia.

    • Duly informed patients who have signed the informed consent during the preanesthesia consultation, or after a period of consideration if necessary, expressing their consent to be included in the study.

    • Between 18-45 years of age.

    • ASA I and II.

    • Sufficient intellectual ability to understand the technique as well as the equipment being used.

    Exclusion Criteria:
    • Failure to meet any of the above criteria.

    • Presence of a major medical, cardiovascular, pulmonary, metabolic, renal or liver disorder.

    • Preeclampsia and/or HELLP syndrome.

    • Coagulopathy

    • Profuse bleeding greater than 1000 ml or that which provokes hemodynamic instability that requires aggressive fluid therapy and/or transfusion.

    • Allergy to any drug included in the protocol.

    • Psychiatric or neurological pathology.

    • Preexisting infection.

    • Previous treatment with opioids or antidepressants or suffer from chronic pain.

    • History of alcohol or drug abuse or known consumption of medications that interfere with LB metabolism.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Teresa Herrera Hospital; A Coruña University Hospital Complex A Coruña Spain 15008

    Sponsors and Collaborators

    • Manuel Ángel Gómez-Ríos

    Investigators

    • Principal Investigator: Manuel Á gómez-Ríos, MD, C.H.U. A Coruña

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Manuel Ángel Gómez-Ríos, Principal Investigator, Complexo Hospitalario Universitario de A Coruña
    ClinicalTrials.gov Identifier:
    NCT01458431
    Other Study ID Numbers:
    • MGR-LB-2010-01
    First Posted:
    Oct 24, 2011
    Last Update Posted:
    Dec 23, 2014
    Last Verified:
    Oct 1, 2011
    Keywords provided by Manuel Ángel Gómez-Ríos, Principal Investigator, Complexo Hospitalario Universitario de A Coruña
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 23, 2014